欧洲蛋白质体学市场（按产品、应用和国家划分）分析与预测（2024 年至 2034 年）

预计欧洲蛋白质体学市场规模将从 2024 年的 87.7 亿美元成长到 2034 年的 274.3 亿美元，2024-2034 年预测期间的复合年增长率为 12.07%。

质谱和次世代定序技术的进步使得蛋白质分析越来越准确，推动了欧洲蛋白质体学市场的成长。此外，由于人们努力发现新的生物标记和改善疾病分析，个人化医疗活动不断增加，因此需求也在增加。欧盟计画的强大研究资金、日益增长的官民合作关係以及医院、生物技术公司和学术界之间的战略联盟正在推动新兴蛋白质组学应用的发展。同时，欧洲人口老化和慢性病的增加凸显了对更好的诊断和早期检测技术的需求，使得蛋白质体学成为该地区临床创新和生命科学研发环境的关键组成部分。

市场介绍

随着越来越多的临床研究机构、製药公司和生命科学研究人员意识到分析蛋白质水平有助于了解疾病原因、发现生物标记并加速药物开发，欧洲蛋白质组学市场正在快速成长。在高解析度质谱、微流体样品製备和先进生物资讯学不断进步的推动下，区域供应商和服务供应商正在引入整合系统，以优化从样品输入到数据解释的工作流程。透过公共和私人资金流（从国家研究项目到地平线欧洲基金）加速肿瘤学、免疫学和神经退化领域的转化计划，推动了对发现规模和有针对性的蛋白质组学解决方案的需求。

透过改善对尖端单细胞和空间蛋白质组学技术的获取，产学研合作和联盟使研究人员能够绘製组织微环境中的细胞异质性图并确定新的治疗标靶。临床实验室正在逐步检验多反应监测试验和无标定定量方法，用于伴随诊断和患者分层，为更广泛的监管核准和报销奠定基础。透过对核心设施和数据分析技能的基础设施投资，蛋白质体学已牢固确立为西欧和北欧以及新兴的东欧中心个性化和精准医疗议程的关键组成部分。

展望未来，市场参与者期望通讯协定进一步标准化，多组体学资料流之间的互通性得到改善，并扩大与云端处理供应商的合作，以降低进入门槛并为疫苗开发、生物标记检验和即时治疗效果相关人员开闢新的途径。

欧洲蛋白质体学市场趋势、驱动因素与挑战

趋势

• 高分辨率质谱仪与单细胞和空间蛋白质组学工作流程的整合度不断提高
• 扩展蛋白质体学、基因组学和代谢体学相结合的多体学学平台
• 越来越多地采用无标定定量和数据独立采集来实现更深入的蛋白质组覆盖
• 云端基础的生物资讯学和人工智慧主导的数据分析流程的出现
• 标靶蛋白质体学 (PRM/MRM) 在临床检测开发的应用日益广泛

驱动程式

• 强大的欧盟和国家资助计划，支持生物标誌物的发现和转化研究
• 对精准医疗解决方案的需求，包括伴随诊断和分层患者照护
• 产学合作和联盟的发展加速了技术检验
• 药物开发中高级安全性和有效性测试的监管激励措施
• 改善早期疾病检测和治疗反应监测的压力

任务

• 最先进的设备和专业人员的资本和营运成本高昂
• 复杂的样品製备工作流程与实验室间的差异
• 庞大的蛋白质体学资料集和缺乏统一的标准造成了资料管理瓶颈
• 蛋白质体学诊断的临床验证和监管途径有限
• 需要建立强大的品管架构和实验室间可重复性研究

产品/创新策略：欧洲蛋白质体学市场大致按产品、应用和国家等不同类别细分。这有助于读者清楚地了解哪个部分占有最大份额以及哪个部分在未来几年可能会成长。

竞争策略：欧洲蛋白质体学市场有许多现有参与者，拥有自己的产品和服务组合。本研究分析和介绍的欧洲蛋白质体学市场的主要企业概况包括提供蛋白质体学产品和服务的知名公司。

主要市场参与企业及竞争格局

所介绍的公司是根据从顶尖专家收集的资讯、分析公司的覆盖范围、类型组合和市场渗透率而选出的。

本报告研究了欧洲蛋白质体学市场，概述了市场，详细介绍了产品、应用和国家趋势，以及参与市场的公司概况。

目录

执行摘要

第一章 市场

• 市场展望
• 主要发现
• 欧洲蛋白质体学市场概况
• 产业展望
  • 供应链概览
• 趋势：现况与未来影响评估
  • 推进端到端蛋白质体学工作流程的自动化
  • 市场参与企业之间的众多合作
  • 扩大蛋白质体学研究以识别疾病生物标记
• 专利分析
  • 专利申请趋势（按国家和年份）
• 法律规范
  • 欧洲联盟
• 产品基准
• 市场动态概览
  • 市场驱动因素
  • 市场限制
  • 市场机会

2. 蛋白质体学市场（按地区划分），百万美元，2022-2034 年

• 区域摘要
• 欧洲
  • 区域概况
  • 市场成长动力
  • 成长抑制因素
  • 欧洲蛋白质体学市场应用状况
  • 欧洲蛋白质体学市场（按产品提供）
  • 法国
  • 义大利
  • 德国
  • 英国
  • 西班牙
  • 其他的

第三章 市场竞争基准化分析与公司概况

• 蛋白质体学市场：竞争格局
  • 企业策略 2022 年 1 月 - 2024 年 12 月
  • 伙伴关係、联盟和业务扩展
  • 合併与收购
  • 新服务
• 公司简介
  • Biognosys AG
  • DiaSorin SpA
  • Merck KGaA
  • Oxford Expression Technologies Ltd.

第四章调查方法

Introduction to Europe Proteomics Market

The Europe proteomics market is projected to reach $27.43 billion by 2034 from $8.77 billion in 2024, growing at a CAGR of 12.07% during the forecast period 2024-2034. Advances in mass spectrometry and next-generation sequencing technologies, which provide ever-increasing precision in protein analysis, are driving the proteomics market's growth in Europe. Demand is further increased by a rise in personalised healthcare activities, which are fuelled by initiatives to find new biomarkers and improve disease profiling. New proteomic applications are being accelerated by strong research funding from EU programs, expanding public-private partnerships, and strategic alliances between hospitals, biotech companies, and academia. In the meantime, Europe's ageing population and increasing prevalence of chronic diseases highlight the need for better diagnostics and early detection techniques, solidifying proteomics as a key component of the region's clinical innovation and life-science R&D environment.

Market Introduction

The market for proteomics in Europe is growing rapidly as more and more clinical labs, pharmaceutical companies, and life science researchers realise how effective protein-level analysis is in understanding disease causes, finding biomarkers, and speeding up drug development. Regional vendors and service providers are launching integrated systems that optimise workflows from sample input to data interpretation, driven by ongoing advancements in high-resolution mass spectrometry, microfluidic sample preparation, and advanced bioinformatics. The need for both discovery-scale and targeted proteomics solutions is being driven by the acceleration of translational projects in oncology, immunology, and neurodegeneration through public and private funding streams, ranging from national research efforts to Horizon Europe funds.

By increasing access to state-of-the-art single-cell and spatial proteomics techniques, academic-industry clinicpartnerships and consortia have made it possible for researchers to map cellular heterogeneity within tissue microenvironments and identify new therapeutic targets. Clinical laboratories are laying the groundwork for wider regulatory approval and reimbursement by progressively validating multiple response monitoring assays and label-free quantification for companion diagnostics and patient stratification. Infrastructure investments in core facilities and data-analysis skills are solidifying proteomics as a key component of personalised and precision medicine plans throughout Western Europe, the Nordics, and rising Eastern European hubs.

In the future, market players expect that further standardisation of protocols, improved interoperability between multi-omics data streams, and expanding collaborations with cloud computing providers will reduce entry barriers and open up new avenues for vaccine development, biomarker validation, and real-time therapeutic efficacy monitoring.

Market Segmentation

Segmentation 1: by Offering

• Product
• Service

Segmentation 2: by Application

• Drug Discovery
• Clinical Diagnostics
• Others

Segmentation 3: by Region

• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest-of-Europe

Europe Proteomics Market Trends, Drivers and Challenges

Trends

• Growing integration of high-resolution mass spectrometers with single-cell and spatial proteomics workflows
• Expansion of multi-omics platforms combining proteomics with genomics and metabolomics
• Increased adoption of label-free quantitation and data-independent acquisition for deeper proteome coverage
• Emergence of cloud-based bioinformatics and AI-driven data analysis pipelines
• Rising use of targeted proteomics (PRM/MRM) in clinical assay development

Drivers

• Strong EU and national funding programmes supporting biomarker discovery and translational research
• Demand for precision medicine solutions, including companion diagnostics and stratified patient care
• Growth of academic-industry partnerships and consortia accelerating technology validation
• Regulatory encouragement for advanced safety and efficacy testing in drug development
• Pressure to improve early-stage disease detection and monitor therapeutic responses

Challenges

• High capital and operational costs for state-of-the-art instrumentation and specialized personnel
• Complex sample preparation workflows and variability across laboratories
• Data management bottlenecks due to massive proteomic datasets and lack of harmonized standards
• Limited clinical validation and regulatory pathways for proteomics-based diagnostics
• Need for robust quality-control frameworks and inter-laboratory reproducibility studies

How can this report add value to an organization?

Product/Innovation Strategy: The Europe proteomics market has been extensively segmented based on various categories, such as offering, application, and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe proteomics market has numerous established players with product and service portfolios. Key players in the Europe proteomics market analyzed and profiled in the study involve established players offering proteomics products and services.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, type portfolio, and market penetration.

Some prominent names in the Europe proteomics market include:

• Biognosys AG
• DiaSorin S.p.A.
• Merck KGaA

Table of Contents

Executive Summary

Scope and Definition

1 Market

• 1.1 Market Outlook
  • 1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics
  • 1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations
• 1.2 Key Findings
• 1.3 Europe Proteomics Market Scenario
  • 1.3.1 Realistic Scenario
  • 1.3.2 Optimistic Scenario
  • 1.3.3 Pessimistic Scenario
• 1.4 Industry Outlook
  • 1.4.1 Supply Chain Overview
• 1.5 Trends: Current and Future Impact Assessment
  • 1.5.1 Increasing Automation for End-to-End Proteomics Workflow
  • 1.5.2 Significant Number of Collaborations among Market Players
  • 1.5.3 Growing Proteomics Research to Identify Disease Biomarkers
• 1.6 Patent Analysis
  • 1.6.1 Patent Filing Trend (by Country, Year)
• 1.7 Regulatory Framework
  • 1.7.1 European Union (EU)
    • 1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
      • 1.7.1.1.1 EU Medical Device Regulation
      • 1.7.1.1.2 EU In Vitro Diagnostic Regulation
    • 1.7.1.2 Regulatory Requirements for Clinical Proteomics Labs in the EU
• 1.8 Product Benchmarking
• 1.9 Market Dynamics Overview
  • 1.9.1 Market Drivers
    • 1.9.1.1 Increasing Prevalence of Chronic Diseases
    • 1.9.1.2 Increasing Technological Advancements
    • 1.9.1.3 Advancements in Personalized Medicine and Drug Discovery
  • 1.9.2 Market Restraints
    • 1.9.2.1 Shortage of Skilled Professionals
    • 1.9.2.2 Complexity in Analyzing Data of Proteomics Research
  • 1.9.3 Market Opportunities
    • 1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes

2 Proteomics Market (by Region), $Million, 2022-2034

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 Europe Proteomics Market, by Application
  • 2.2.5 Europe Proteomics Market, by Offering
    • 2.2.5.1 Europe Proteomics Market, by Product
  • 2.2.6 France
    • 2.2.6.1 France Proteomics Market, by Application
    • 2.2.6.2 France Proteomics Market, by Offering
      • 2.2.6.2.1 France Proteomics Market, by Product
  • 2.2.7 Italy
    • 2.2.7.1 Italy Proteomics Market, by Application
    • 2.2.7.2 Italy Proteomics Market, by Offering
      • 2.2.7.2.1 Italy Proteomics Market, by Product
  • 2.2.8 Germany
    • 2.2.8.1 Germany Proteomics Market, by Application
    • 2.2.8.2 Germany Proteomics Market, by Offering
      • 2.2.8.2.1 Germany Proteomics Market, by Product
  • 2.2.9 U.K.
    • 2.2.9.1 U.K. Proteomics Market, by Application
    • 2.2.9.2 U.K. Proteomics Market, by Offering
      • 2.2.9.2.1 U.K. Proteomics Market, by Product
  • 2.2.10 Spain
    • 2.2.10.1 Spain Proteomics Market, by Application
    • 2.2.10.2 Spain Proteomics Market, by Offering
      • 2.2.10.2.1 Spain Proteomics Market, by Product
  • 2.2.11 Rest-of-Europe
    • 2.2.11.1 Rest-of-Europe Proteomics Market, by Application
    • 2.2.11.2 Rest-of-Europe Proteomics Market, by Offering
      • 2.2.11.2.1 Rest-of-Europe Proteomics Market, by Product

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Proteomics Market: Competitive Landscape
  • 3.1.1 Corporate Strategies, January 2022-December 2024
  • 3.1.2 Partnerships, Alliances, and Business Expansions
  • 3.1.3 Mergers and Acquisitions
  • 3.1.4 New Offerings
• 3.2 Company Profiles
  • 3.2.1 Biognosys AG
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products/ Services
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 DiaSorin S.p.A.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products/ Services
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Merck KGaA
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products/ Services
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Oxford Expression Technologies Ltd.
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products/ Services
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Proteomics Market (by Application), $Billion, 2022, 2027, and 2034
• Figure 2: Europe Proteomics Market (by Product), $Billion, 2022, 2027, and 2034
• Figure 3: Key Events to Keep Track of within the Proteomics Market
• Figure 4: Europe Proteomics Market Size, $Billion, 2022-2034
• Figure 5: Proteomics Literature Published (January 2015 to December 2024)
• Figure 6: Europe Proteomics Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2034
• Figure 7: Europe Proteomics Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022 to 2034
• Figure 8: Europe Proteomics Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022 to 2034
• Figure 9: Supply Chain and Risks within the Supply Chain
• Figure 10: Key Features of End-to-End Proteomics Workflow
• Figure 11: Proteomics Market, Patent Analysis (by Country), January 2021-December 2024
• Figure 12: Proteomics Market, Patent Analysis (by Year), January 2021-December 2024
• Figure 13: Proteomics Market, Product Benchmarking (by Product)
• Figure 14: Impact Analysis of Market Navigating Factors, 2024-2034
• Figure 15: Timeline on the Personalized Medicine Journey of Protein
• Figure 16: Difficulties Faced in Top-Down Proteomics
• Figure 17: Future Outlook of Nanoproteomics
• Figure 18: Europe Proteomics Market, $Billion, 2022-2034
• Figure 19: Proteomics Literature Published in Canada (January 2015 to December 2024)
• Figure 20: France Proteomics Market, $Billion, 2022-2034
• Figure 21: Proteomics Literature Published in Italy (January 2015 to December 2024)
• Figure 22: Italy Proteomics Market, $Billion, 2022-2034
• Figure 23: Proteomics Literature Published in Germany (January 2015 to December 2024)
• Figure 24: Germany Proteomics Market, $Billion, 2022-2034
• Figure 25: Proteomics Literature Published in the U.K. (January 2015 to December 2024)
• Figure 26: U.K. Proteomics Market, $Billion, 2022-2034
• Figure 27: Proteomics Literature Published in Spain (January 2015 to December 2024)
• Figure 28: Spain Proteomics Market, $Billion, 2022-2034
• Figure 29: Rest-of-Europe Proteomics Market, $Billion, 2022-2034
• Figure 30: Corporate Strategies, January 2022-December 2024
• Figure 31: Acquisitions (by Company), January 2022-December 2024
• Figure 32: New Offerings Share (by Company), January 2022-December 2024
• Figure 33: Data Triangulation
• Figure 34: Top-Down and Bottom-Up Approach
• Figure 35: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Opportunities across Regions
• Table 3: The Diversified Exposure of Proteomics
• Table 4: Comparative Analysis of Proteomics: Advantages and Disadvantages Over Other Omics Approaches
• Table 5: Introduction to Proteomics Techniques: Principles, Advantages, and Limitations
• Table 6: Comparison of Existing and Emerging Paradigms in Proteomics Technologies
• Table 7: Proteomics Market Trend Analysis
• Table 8: Some of the Partnerships and Collaborations in the Proteomics Market
• Table 9: List of Molecular Targets Identified with Proteomics
• Table 10: Cancer Cases Expected Between 2020 and 2040
• Table 11: Proteomics Market, Regulatory Approvals, and New Offerings
• Table 12: Cancer Biomarkers Discovered by Proteomics and its Applications in Personalized Medicine
• Table 13: Proteomics Market (by Region), $Billion, 2022-2034
• Table 14: Europe Proteomics Market (by Application), $Billion, 2022-2034
• Table 15: Europe Proteomics Market (by Offering), $Billion, 2022-2034
• Table 16: Europe Proteomics Market (by Product), $Billion, 2022-2034
• Table 17: France Proteomics Market (by Application), $Billion, 2022-2034
• Table 18: France Proteomics Market (by Offering), $Billion, 2022-2034
• Table 19: France Proteomics Market (by Product), $Billion, 2022-2034
• Table 20: Italy Proteomics Market (by Application), $Billion, 2022-2034
• Table 21: Italy Proteomics Market (by Offering), $Billion, 2022-2034
• Table 22: Italy Proteomics Market (by Product), $Billion, 2022-2034
• Table 23: Germany Proteomics Market (by Application), $Billion, 2022-2034
• Table 24: Germany Proteomics Market (by Offering), $Billion, 2022-2034
• Table 25: Germany Proteomics Market (by Product), $Billion, 2022-2034
• Table 26: U.K. Proteomics Market (by Application), $Billion, 2022-2034
• Table 27: U.K. Proteomics Market (by Offering), $Billion, 2022-2034
• Table 28: U.K. Proteomics Market (by Product), $Billion, 2022-2034
• Table 29: Spain Proteomics Market (by Application), $Billion, 2022-2034
• Table 30: Spain Proteomics Market (by Offering), $Billion, 2022-2034
• Table 31: Spain Proteomics Market (by Product), $Billion, 2022-2034
• Table 32: Rest-of-Europe Proteomics Market (by Application), $Billion, 2022-2034
• Table 33: Rest-of-Europe Proteomics Market (by Offering), $Billion, 2022-2034
• Table 34: Rest-of-Europe Proteomics Market (by Product), $Billion, 2022-2034
• Table 35: Partnerships, Alliances, and Business Expansions (by Company), January 2022-December 2024